These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33074853)

  • 1. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach.
    Chou A; Ahadi M; Arena J; Sioson L; Sheen A; Fuchs TL; Pavlakis N; Clarke S; Kneebone A; Hruby G; Sahni S; Mittal A; Samra J; Gill AJ
    Am J Surg Pathol; 2021 Mar; 45(3):394-404. PubMed ID: 33074853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
    Matsuda Y; Ohkubo S; Nakano-Narusawa Y; Fukumura Y; Hirabayashi K; Yamaguchi H; Sahara Y; Kawanishi A; Takahashi S; Arai T; Kojima M; Mino-Kenudson M
    Sci Rep; 2020 Oct; 10(1):18278. PubMed ID: 33106543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    Kim SS; Ko AH; Nakakura EK; Wang ZJ; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Kim GE
    Am J Surg Pathol; 2019 Mar; 43(3):334-340. PubMed ID: 30211728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
    Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy.
    Ahn S; Lee JC; Kim J; Kim YH; Yoon YS; Han HS; Kim H; Hwang JH
    Gut Liver; 2022 Jan; 16(1):129-137. PubMed ID: 33875622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
    Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
    Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.
    Kawai M; Hirono S; Okada KI; Miyazawa M; Shimizu A; Kitahata Y; Kobayashi R; Ueno M; Hayami S; Tanioka K; Yamaue H
    Surgery; 2019 Jun; 165(6):1151-1160. PubMed ID: 30765142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
    N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
    J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
    Polish A; Joseph NE; Marsh RW
    Am J Clin Oncol; 2019 Oct; 42(10):761-766. PubMed ID: 31569128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple matrix to predict treatment success and long-term survival among patients undergoing pancreatectomy.
    Fitzgerald TL; Hunter L; Mosquera C; Jindal C; Biswas T; Zervos E; Efird JT
    HPB (Oxford); 2019 Feb; 21(2):204-211. PubMed ID: 30087052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy.
    Christians KK; Heimler JW; George B; Ritch PS; Erickson BA; Johnston F; Tolat PP; Foley WD; Evans DB; Tsai S
    Surgery; 2016 Mar; 159(3):893-900. PubMed ID: 26602840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphological aspects of the hepatic response to neoadjuvant therapy.
    Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C
    Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of resection margin status on survival in pancreatic cancer patients after neoadjuvant treatment and pancreatoduodenectomy.
    Maeda S; Moore AM; Yohanathan L; Hata T; Truty MJ; Smoot RL; Cleary SP; Nagorney DM; Grotz TE; Park EJ; Girgis MD; Reber HA; Motoi F; Masuda T; Unno M; Kendrick ML; Donahue TR
    Surgery; 2020 May; 167(5):803-811. PubMed ID: 31992444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base.
    Mirkin KA; Hollenbeak CS; Wong J
    Int J Surg; 2016 Oct; 34():96-102. PubMed ID: 27573691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
    Czosnyka NM; Borgert AJ; Smith TJ
    HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy.
    van Veldhuisen E; Vogel JA; Klompmaker S; Busch OR; van Laarhoven HWM; van Lienden KP; Wilmink JW; Marsman HA; Besselink MG
    HPB (Oxford); 2018 Jul; 20(7):605-611. PubMed ID: 29475787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.